Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634561

Cover Image

PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1634561

Recurrent High Grade Serous Ovarian Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 5-7 business days
SELECT AN OPTION
PPT (Single User License)
USD 5900
PPT (2 - 3 User License)
USD 6500
PPT (Site License - Up to 10 Users)
USD 9900
PPT (Enterprise License)
USD 14999

Add to Cart

The most prevalent form of ovarian cancer is high-grade serous ovarian cancer (HGSOC). High-grade serous ovarian cancer affects about two thirds of those who are diagnosed with the disease. Half of those who are diagnosed with it are older women, who are typically older women. The Ovarian Cancer Research Association (OCRA) estimates that the risk of ovarian cancer recurrence as follows: 10% if the cancer is detected and treated early; 30% if the cancer is discovered and treated in the second stage; 70% to 90% if discovered and treated at stage 3; and 90% to 95% if discovered and treated at stage 4. In total, about 70% of ovarian cancer patients will experience a recurrence. The poor prognosis of this malignant tumor is largely explained by the fact that most women are diagnosed at a late stage. The BRCA1 and BRCA2 genes, which produce the proteins needed for homologous recombination to repair double-stranded DNA damage, are subject to germline mutations that raise the risk of developing cancer.

Description

The most typical form of ovarian cancer is high-grade serous (HGSOC). High-grade serous ovarian cancer affects roughly two thirds of those who are diagnosed with the disease. Half of the women who receive a diagnosis are older than 60, which is the typical demographic for those affected. Epithelial ovarian tumors make up about 90% of ovarian cancer cases. On the exterior of the ovaries and fallopian tubes, epithelial cells are where they develop. Serous cell carcinoma is the most prevalent subtype of epithelial ovarian cancer. As far as gynaecological cancers go, epithelial ovarian cancer is the deadliest. Stages 2b to 4 of the International Federation of Gynaecology and Obstetrics (FIGO) correspond to the majority of patients' ovarian cancer diagnoses, which occur when the disease has advanced to an advanced stage involving the abdominal cavity and other organs. This explains why this malignancy has a poor prognosis. Ninety% of primary ovarian tumors are epithelial in origin, and there are numerous histological subtypes of this disease, including serous, mucinous, endometrioid, clear cell, transitional cell (Brenner's tumor), mixed, and undifferentiated. The full extent of the carcinogenicity of epithelial ovarian cancer is unknown. The dual carcinogenesis model suggests that there are two types of ovarian cancer: type I and type II. Serous, mucinous, endometrioid, low-grade recurrent, and Brenner tumors are examples of type I tumors. Mutations in the signaling pathway genes KRAS, BRAF, PTEN, PIK3CA, CTNNB1, ARID1A, and PPP2R1A are its hallmarks, and it typically has an indolent course. Serous, endometrioid, and high-grade undifferentiated carcinomas are all types II tumors, which are the most prevalent. They are aggressive, genetically unstable, and frequently discovered much too late. Type I tumors rarely have the mutations found in type II tumors, whereas p53 and BRCA gene mutations are frequently found.

Recurrent High Grade Serous Ovarian Cancer (Epidemiology)

The risk of ovarian cancer recurrence, according to the Ovarian Cancer Research Association (OCRA), is as follows: 10% if the cancer is detected and treated early; 30% if detected and treated in the second stage; 70% to 90% if detected and treated at stage 3; 90% to 95% if detected and treated at stage 4; overall, about 70% of ovarian cancer patients will return. Numerous relapses have occurred in some people. With more than 313,000 new cases and more than 207,000 fatalities in 2020, ovarian cancer will rank as the eighth most common cancer in women globally. In Brunei, the age ratio is the highest at 17.4, while the global average is 6.6 per 100,000 people. Based on data from 2015 to 2019, the incidence of ovarian cancer in the United States is 10.6 per 100,000 women annually. of the year's cases. Ovarian cancer incidence has decreased by about 1% annually in women under the age of 65 since at least the mid-1970s, but it has only started to decline in older women since the early 1990s. White women were more likely than Black women to develop ovarian cancer (11.0 and 9.0 per 100,000 woman-years, respectively). Despite the fact that epithelial ovarian cancer can strike girls as young as 15, the average age at diagnosis is 63, and the majority of cases are found in women between the ages of 55 and 64. The estimated lifetime risk in the US is 1.22%. According to the American Cancer Society, there will be 19.88 new cases of ovarian cancer identified in 2022, and 12,810 women will pass away from the condition. Ovarian cancer is the fifth most common cause of cancer-related death in women, accounting for 5% more cancer deaths than any other cancer of the female reproductive system, despite being the 18th most common cancer in women. The annual average reduction in ovarian cancer mortality between 2010 and 2019 was 2.7%. The average death age was 70.

Recurrent High Grade Serous Ovarian Cancer -Current Market Size & Forecast Trends

The market for recurrent high-grade serous ovarian cancer (rHGSOC) is projected to grow significantly, with estimates indicating a value of approximately USD 1.43 billion in 2023, expected to reach around USD 1.53 billion in 2024, and further grow at a compound annual growth rate (CAGR) of 9.15%, reaching about USD 2.64 billion by 2030. The growth is driven by advancements in treatment options, particularly the development of PARP inhibitors and immunotherapies, which have shown promise in improving patient outcomes. Additionally, increasing awareness of ovarian cancer and the rising prevalence of rHGSOC are contributing to market expansion. As research continues to evolve and new therapies emerge, the rHGSOC market is well-positioned for significant growth through 2035.

The fact that most women receive their diagnoses at a late stage largely accounts for the malignant tumor's poor prognosis. The BRCA1 and BRCA2 genes, which produce the proteins needed for homologous recombination to repair double-stranded DNA damage, are subject to germline mutations that raise the risk of developing cancer. Approximately 5% of people with BRCA mutations. 14% of ovarian cancers are epithelial. Additionally, somatic BRCA mutations have been reported. Currently, combination chemotherapy, typically carboplatin and paclitaxel, is the first line of treatment for high-grade epithelial ovarian cancer after bariatric surgery. Chemotherapy based on platinum is very effective against ovarian cancer. Despite mixed results, the standard of care for primary care is still the combination of carboplatin AUC 5 and paclitaxel (175 mg/m2 intravenously every 3 hours every 21 days). Studies on the upper registry have revealed a 70-80% recurrence rate in the first two years. After the first round of chemotherapy, the majority of patients will enter remission, but most will eventually relapse. Because randomized clinical trials have not demonstrated a significant improvement in progression-free survival, targeted therapies, such as the antiangiogenic drug bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors, have been approved for the treatment of ovarian cancer. Regarding acceptability and quality of life, it had no negative effects. Olaparib, the first PARP inhibitor to receive FDA approval, is currently regarded as the only form of maintenance therapy for people with recurrent ovarian cancer and BRCA mutations who have experienced a full or partial response to platinum-based chemotherapy.

Report Highlights

Recurrent High Grade Serous Ovarian Cancer - Current Market Trends

Recurrent High Grade Serous Ovarian Cancer - Current & Forecasted Cases across the G8 Countries

Recurrent High Grade Serous Ovarian Cancer - Market Opportunities and Sales Potential for Agents

Recurrent High Grade Serous Ovarian Cancer - Patient-based Market Forecast to 2035

Recurrent High Grade Serous Ovarian Cancer - Untapped Business Opportunities

Recurrent High Grade Serous Ovarian Cancer - Product Positioning Vis-a-vis Competitors' Products

Recurrent High Grade Serous Ovarian Cancer - KOLs Insight

Table of Content

1. Recurrent High Grade Serous Ovarian Cancer Background

  • 1.1. Recurrent High Grade Serous Ovarian Cancer Definition
  • 1.2. Signs and Symptoms
  • 1.3. Pathogenesis
  • 1.4. Clinical Manifestation
  • 1.5. Recurrent High Grade Serous Ovarian Cancer biomarkers
  • 1.6. Diagnosis

2. Epidemiology Estimated and Forecast to 2035

  • 2.1. Epidemiology Research Method & Data Sources Used
  • 2.2. United States
    • 2.2.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.2.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.3. United Kingdom
    • 2.3.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.3.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.4. Spain
    • 2.4.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.4.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.5. Germany
    • 2.5.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.5.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.6. France
    • 2.6.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.6.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.7. Italy
    • 2.7.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.7.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.8. Japan
    • 2.8.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.8.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.9. China
    • 2.9.1. Incident Cases of Recurrent High Grade Serous Ovarian Cancer
    • 2.9.2. Diagnosed and treatable cases of Recurrent High Grade Serous Ovarian Cancer by line of therapies (LOT)
  • 2.10. Current Unmet Needs in Recurrent High Grade Serous Ovarian Cancer

3. Current Treatment Paradigm

  • 3.1. Treatment/Prevention guidelines
  • 3.2. Regulatory Approvals/Indication and Current Benchmarks

4. KOLs Insight (US, EU, JP, CH)

  • 4.1. Unmet Needs
  • 4.2. Analysis of the progress in terms of approvals & current pipeline
  • 4.3. Impact on the treatment algorithm and product positioning
  • 4.4. Relevance of new targets/platforms/ Therapy Uptake Share %
  • 4.5. Physicians Preferences for the new pharmacological agents

5. What's New in 2024/2025

6. Future Treatment Paradigm

  • 6.1. Recurrent High Grade Serous Ovarian Cancer Competitor Landscape and Approvals Anticipated
  • 6.2. Future Treatment Algorithms and Competitor Positioning
  • 6.3. Key Data Summary for Emerging Treatment

7. Late Phase Therapies Strategic Considerations in Recurrent High Grade Serous Ovarian Cancer

8. Total Market Forecast

  • 8.1. Key Summary Findings
    • 8.1.1. G8 total Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 8.1.2. G8 total Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)

9. Market Forecast by Country

  • 9.1. United States
    • 9.1.1. United States Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.1.2. United States Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.2. Germany
    • 9.2.1. Germany Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.2.2. Germany Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.3. France
    • 9.3.1. France Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.3.2. France Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.4. Italy
    • 9.4.1. Italy Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.4.2. Italy Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.5. Spain
    • 9.5.1. Spain Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.5.2. Spain Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.6. United Kingdom
    • 9.6.1. United Kingdom Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.6.2. United Kingdom Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.7. Japan
    • 9.7.1. Japan Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.7.2. Japan Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)
  • 9.8. China
    • 9.8.1. China Market for Recurrent High Grade Serous Ovarian Cancer 2022-2035 (USD Million)
    • 9.8.2. China Market for Recurrent High Grade Serous Ovarian Cancer by Therapies 2022-2035 (USD Million)

10. Market Drivers and Barriers

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!